Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study

MT Newswires Live

Sep 10, 2024

Jasper Therapeutics (JSPR) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b/2a asthma challenge study assessing briquilimab, an antibody therapy for mast cell-driven diseases.

The phase 1b/2a asthma study is expected to enroll 30 patients across 10 sites in Canada and the European Union, aiming to validate briquilimab's efficacy, with dosing beginning in Q4 and results expected in H2 2025, the company said.

The biotechnology company also said its c-Kit Mouse model has received a registered trademark from the US Patent and Trademark Office for its ability to test c-Kit or CD117 inhibitors in various diseases.

Price: 18.92, Change: -0.38, Percent Change: -1.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2466545174"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466545174\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466545174?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466545174","market":"hk","top_or_hot":-1,"title":"Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study","media":"MT Newswires Live","content":"<html><body><p><a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a> Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study</p><p> Jasper <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (JSPR) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b/2a asthma challenge study assessing briquilimab, an antibody therapy for mast cell-driven diseases.</p><p>The phase 1b/2a asthma study is expected to enroll 30 patients across 10 sites in Canada and the European Union, aiming to validate briquilimab's efficacy, with dosing beginning in Q4 and results expected in H2 2025, the company said.</p><p>The biotechnology company also said its c-Kit Mouse model has received a registered trademark from the US Patent and Trademark Office for its ability to test c-Kit or CD117 inhibitors in various diseases.</p><p>Price: 18.92, Change: -0.38, Percent Change: -1.97</p></body></html>","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study Jasper Therapeutics (JSPR) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466545174","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466545174","pubTimestamp":1725979258,"columns":[],"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study Jasper Therapeut","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","A7RU.SI":"吉宝基础设施信托","JSPR":"Jasper Therapeutics"},"translate_title":"Jasper Therapeutics表示加拿大卫生部批准了1b/2a期Briquilimab哮喘研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JSPR":1,"A7RU.SI":1},"content_text":"Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study Jasper Therapeutics (JSPR) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b/2a asthma challenge study assessing briquilimab, an antibody therapy for mast cell-driven diseases.The phase 1b/2a asthma study is expected to enroll 30 patients across 10 sites in Canada and the European Union, aiming to validate briquilimab's efficacy, with dosing beginning in Q4 and results expected in H2 2025, the company said.The biotechnology company also said its c-Kit Mouse model has received a registered trademark from the US Patent and Trademark Office for its ability to test c-Kit or CD117 inhibitors in various diseases.Price: 18.92, Change: -0.38, Percent Change: -1.97","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}